Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

Core Viewpoint - DJS Law Group is investigating Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding a clinical study [1][2]. Investigation Details - The investigation centers on Larimar's September 29, 2025 announcement of an open-label study involving daily subcutaneous injections of Nomlabofusp for Friedreich's Ataxia, which was presented as having positive results despite severe allergic reactions experienced by multiple participants [2]. - Following the release of this information, Larimar's shares experienced a significant decline of 33.66% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].